<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00981149</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00040504</org_study_id>
    <nct_id>NCT00981149</nct_id>
  </id_info>
  <brief_title>Duloxetine for Treatment of Painful Temporomandibular Joint Disorder</brief_title>
  <official_title>Duloxetine for Treatment of Painful Temporomandibular Joint Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Temporomandibular joint disorders (TMJD) are a family of musculoskeletal disorders that&#xD;
      represent the most common chronic orofacial pain condition. TMJD is associated with&#xD;
      persistent pain in the region of the temporomandibular joint and muscles of the head and&#xD;
      neck. The purpose of this study is to test duloxetine (Cymbalta) as a potential treatment for&#xD;
      chronic facial pain. Duloxetine is FDA approved as an antidepressant and for the chronic pain&#xD;
      conditions of fibromyalgia and diabetic neuropathy. Chronic facial pain may be linked to&#xD;
      Temporomandibular Joint Disorder (TMJD) which currently has no standard treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed clinical trial will evaluate the analgesic and adverse effects of duloxetine, a&#xD;
      serotonin and norepinephrine reuptake inhibitor, in comparison to placebo in patients with&#xD;
      temporomandibular joint disorder (TMJD). Duloxetine is approved as an antidepressant and has&#xD;
      been shown effective in the chronic pain conditions of fibromyalgia and diabetic neuropathy.&#xD;
      Decrease in pain and dysfunction and improvement in quality of life and global satisfaction&#xD;
      will be assessed over 6 weeks. Successful demonstration of a therapeutic effect may provide a&#xD;
      basis for clinical use of duloxetine in patients with painful TMJD.&#xD;
&#xD;
      Background&#xD;
&#xD;
      TMJD is a heterogeneous family of musculoskeletal disorders associated with the&#xD;
      temporomandibular joint, the periauricular region, and the muscles of the head and neck. TMJD&#xD;
      has been identified as a major cause of nondental, chronic pain in the craniofacial region,&#xD;
      second only to headache (NIH Technology Assessment Conference, 1997). Although few&#xD;
      population-based epidemiological studies have been conducted, studies report the prevalence&#xD;
      of TMJD as up to 20% in the adult population (Dworkin et al 1990, Schiffman et al 1990).&#xD;
      Dworkin and colleagues conducted a series of studies of TMJD using valid and reliable&#xD;
      examination and survey procedures (Von Korff et al 1988, Dworkin et al 1990, Carlsson and&#xD;
      LeResche 1995) and identified 12.1% of the test population with painful TMJD with a female to&#xD;
      male ratio of approximately 7:1. They also found the annual incidence of developing TMJD to&#xD;
      be just over 2% with females tending to show a higher incidence rate than males (Von Korff et&#xD;
      al 1993). Hence, TMJD is common in the general population, but it has also been reported that&#xD;
      about 20% of patients with early signs and symptoms of TMJD will progress to a persistent&#xD;
      pain state (Schiffman et al 1990).&#xD;
&#xD;
      Several studies of TMJD suggest that patients exhibit a state of CNS hypersensitivity similar&#xD;
      to that reported in fibromyalgia (Maixner et al 1995, Maixner et al 1998, Sarlani and&#xD;
      Greenspan 2003, Sarlani et al 2004) that contributes to the predicted widespread&#xD;
      characteristics of the pain. Genetic factors that impact increased pain sensitivity,&#xD;
      psychological traits and sex differences, and often coupled with environmental stress, may&#xD;
      result in a phenotype that is vulnerable to musculoskeletal disease and susceptible to&#xD;
      selective pharmacological treatment.&#xD;
&#xD;
      In addition to female gender, two other factors predict an elevated incidence of these&#xD;
      disorders: a history of musculoskeletal pain at other body sites and quality of life symptoms&#xD;
      typically associated with depression (Von Korff et al 1988, Raphael and Marbach 2001, John et&#xD;
      al 2003). Patients diagnosed with fibromyalgia often exhibit concurrent orofacial&#xD;
      symptomatology that mimics TMJD (Ta et al 2002, Sarlani and Greenspan 2003, Sarlani et al&#xD;
      2004). These observations and findings suggest that drugs useful for depression, affecting&#xD;
      musculoskeletal systems, and effective in improving central monoaminergic neurotransmission,&#xD;
      are prime candidates for the treatment of TMJD. For these reasons, we hypothesize that&#xD;
      selective noradrenergic or combined noradrenergic and serotonin reuptake inhibitors should be&#xD;
      effective for TMJD.&#xD;
&#xD;
      Lack of research has resulted in a paucity of evidence-based treatment approaches for TMJD&#xD;
      (Antczak- Bouckoms 1995, List 2003). While NSAIDs are sometimes used, there is little&#xD;
      evidence for their effectiveness for TMJD (Dionne 1997, Gordon et al 1990, 1991) except in&#xD;
      frank joint involvement (Ta et al 2004), and gastrointestinal and renal toxicity limit their&#xD;
      long-term use (Gabriel et al 1991, Allison et al 1992, Schafer et al 1995, Champion et al&#xD;
      1997) for treatment of chronic pain. Use of opioids has been discouraged for this chronic&#xD;
      pain condition due to the limitations of long-term use for this drug class (DeNucci et al&#xD;
      1996, Dionne 1997). The most promising pharmacologic therapy for TMJD to date has been&#xD;
      antidepressants, but it is important to note that indication for their clinical use has&#xD;
      primarily been extrapolated from other chronic pain conditions (McQuay et al 1992, Onghena et&#xD;
      al 1992). Only two randomized controlled trials have examined one of the tricyclic&#xD;
      antidepressants (amitryptyline) for TMJD specifically (Sharav et all 1987, Rizzatti-Barbosa&#xD;
      2003). Amitryptyline for TMJD demonstrated an average response rate of 40% in these two&#xD;
      studies, but its adverse effects result in a large percentage of patients discontinuing the&#xD;
      drug before achieving pain relief (DeNucci et al 1996), resulting in an unfavorable risk to&#xD;
      benefit ratio (Zitman et al 1990). Taken together, there has been insufficient evidence to&#xD;
      adopt a pharmacologic standard of care for treatment of TMJD.&#xD;
&#xD;
      Duloxetine has shown efficacy for several chronic pain conditions (Sultan 2008) including&#xD;
      fibromyalgia, and appears to be more effective in women than men (Arnold 2004, 2005). It is&#xD;
      well tolerated and effective at a dose of 60 mg daily ( Sultan 2008). Studies in patients&#xD;
      with fibromyalgia (Arnold 2004, 2005), diabetic neuropathy (Goldstein 2005), low back pain&#xD;
      (Skijaravala 2008), and osteoarthritis (Chappell 2008) have shown an analgesic effect at this&#xD;
      dose with fewer adverse effects and a lower drop out rate than higher doses. In the proposed&#xD;
      study, subjects randomized to the intervention will use 60 mg of duloxetine given as 30 mg&#xD;
      twice daily after a one-week period of 30 mg daily.&#xD;
&#xD;
      Given the prevalence of TMJD and the controversial nature of non-pharmacologic therapies such&#xD;
      as occlusal alteration, intraoral devices, and surgery, the need exists for pharmacologic&#xD;
      treatment that is efficacious but avoids adverse effects that discourage long-term use. This&#xD;
      study will also provide a basis for future investigations of the etiology and management of&#xD;
      painful TMJD.&#xD;
&#xD;
      Purpose/Objective of this study? TMJD represents a prototypic musculoskeletal disease whose&#xD;
      characteristics of associated depression, comorbidity of fibromyalgia, female prevalence,&#xD;
      increased CNS sensitivity to pain, and likely genetic differences among susceptible&#xD;
      individuals, makes it a disorder that will likely be responsive to duloxetine treatment.The&#xD;
      overall objective is to investigate duloxetine as a potential treatment for chronic pain of&#xD;
      TMJD. We hypothesize that subjects receiving duloxetine will experience greater analgesia&#xD;
      than those receiving placebo.&#xD;
&#xD;
      Specifically we will:&#xD;
&#xD;
      1. Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching&#xD;
      placebo at baseline (BL) and follow up over a six week period using the primary outcome&#xD;
      measure of change in spontaneous pain. 2. Evaluate jaw functioning and evoked pain as&#xD;
      measured by range of motion, pain with jaw movement, and pain pressure thresholds. 3. Assess&#xD;
      frequency of adverse effects and their impact on patient global satisfaction and study&#xD;
      adherence. 4. Examine sleep in relationship to pain. 5. Evaluate genetic susceptibilty to&#xD;
      pain and response to duloxetine.&#xD;
&#xD;
      These aims and outcome measures are listed in prioritized order. The study is powered on the&#xD;
      primary outcome measure of spontaneous pain; other measures are exploratory. The study is not&#xD;
      powered to detect subgroup differences for variables such as gender, depression, type of TMJD&#xD;
      diagnosis, or concurrent medications, as described later in the Analysis Plan.&#xD;
&#xD;
      Research Design: The study is a double blind, placebo-controlled parallel groups prospective&#xD;
      study of duloxetine versus placebo. Subjects will be randomized to the investigational&#xD;
      treatment group (duloxetine) or the placebo group. At the time of enrollment they will be&#xD;
      randomly assigned to study drug or placebo by block randomization for order in a 1:1 ratio.&#xD;
      Subjects will be provided acetominophen as a rescue analgesic to use if they feel their pain&#xD;
      is not adequately controlled. The examiners and subjects will be blind to the group&#xD;
      assignment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks.</measure>
    <time_frame>1, 3, 6 weeks</time_frame>
    <description>Measurements from zero to 100 with 100 being the worst pain by Visual Analog Scale (VAS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evoked Pain Via Algometry .</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assessment of evoked pain using digital palpation examination at 18 predefined bodily sites.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Temporomandibular Joint Disorders</condition>
  <arm_group>
    <arm_group_label>duloxetine study drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>duloxetine</intervention_name>
    <description>Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period</description>
    <arm_group_label>duloxetine study drug</arm_group_label>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo match duloxetine for 6 week period.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic TMJD pain of two weeks duration&#xD;
&#xD;
          -  Age 18 and older&#xD;
&#xD;
          -  Confirmed craniofacial pain of nonodontogenic origin by the Research Diagnostic&#xD;
             Criteria for temporomandibular disorders (TMD-RDC)&#xD;
&#xD;
          -  Concomitant medications are permitted, except those which may convey analgesia&#xD;
&#xD;
          -  Females who are neither pregnant, as verified by a urine-based pregnancy test, nor&#xD;
             breast-feeding&#xD;
&#xD;
          -  Female subjects of childbearing potential and those who are post-menopausal for less&#xD;
             than 2 years must be using/willing to use a medically approved method of contraception&#xD;
             (i.e., oral, transdermal or implanted contraceptive devices, intrauterine device,&#xD;
             diaphragm, condom, abstinence, or surgical sterility during the course of the study&#xD;
&#xD;
          -  Able to read and comprehend the rating scales, study instructions, and the consent&#xD;
             form&#xD;
&#xD;
          -  Pain score of 4 or greater on the baseline VAS (0-10)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Undergone any type of TMJ surgery or had TMJ growth disturbances, neoplasm, or injury&#xD;
             to the TMJ area within the past six months&#xD;
&#xD;
          -  Taking analgesic or anti-inflammatory drugs, steroids, antidepressants,&#xD;
             antiepileptics, or opioid medications that may confound the assessment of analgesia&#xD;
&#xD;
          -  Subjects with primary psychiatric diagnosis of major depression, suicidal ideation, or&#xD;
             history of suicide attempt as assessed by medical history and the Mini International&#xD;
             Neuropsychiatric Interview (MINI) are not eligible. Subjects with a score above&#xD;
             average or higher in comparison with normative scores on the Beck Depression Inventory&#xD;
             (BDI) will be allowed to participate&#xD;
&#xD;
          -  Exclusions based on the effects of duloxetine:&#xD;
&#xD;
               -  Known hypersensitivity to duloxetine or its inactive ingredients&#xD;
&#xD;
               -  Subjects with: renal impairment or end stage renal disease; urinary retention or&#xD;
                  hesitation, delayed gastric emptying; substantial alcohol use or evidence of&#xD;
                  chronic liver disease, hepatic insufficiency and hepatotoxicity; bleeding&#xD;
                  disorders, orthostatic hypotension, uncontrolled high blood pressure; recent&#xD;
                  history of myocardial infarction or unstable coronary artery disease; seizure&#xD;
                  disorder, history of bipolar disorder or mania, general anxiety disorder (GAD);&#xD;
                  hyponatremia; uncontrolled narrow-angle glaucoma.&#xD;
&#xD;
               -  Treatment with an monoamine oxidase inhibitor (MAOI) within 30 days of&#xD;
                  randomization, or potential need to use an MAOI during the study or within 5 days&#xD;
                  of discontinuation of the drug&#xD;
&#xD;
               -  Concomitant use of medications such as: NSAIDs, warfarin, aspirin or other drugs&#xD;
                  that affect coagulation; Thioridazine and inhibitors of CYP1A2 which affect&#xD;
                  metabolism of duloxetine; serotonergic drugs like triptans and MAOIs which&#xD;
                  increase the risk of Serotonin Syndrome; drugs that affect gastric acidity&#xD;
&#xD;
          -  Contraindications to acetaminophen use&#xD;
&#xD;
          -  Ever been treated with duloxetine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon M Gordon, DDS MPH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Dental School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Dental School</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2009</study_first_posted>
  <results_first_submitted>October 6, 2017</results_first_submitted>
  <results_first_submitted_qc>October 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2017</results_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Duloxetine Study Drug</title>
          <description>Drug&#xD;
duloxetine: Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: Placebo match duloxetine for 6 week period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duloxetine Study Drug</title>
          <description>Drug&#xD;
duloxetine: Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: Placebo match duloxetine for 6 week period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18 to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks.</title>
        <description>Measurements from zero to 100 with 100 being the worst pain by Visual Analog Scale (VAS).</description>
        <time_frame>1, 3, 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Study Drug</title>
            <description>Drug&#xD;
duloxetine: Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo match duloxetine for 6 week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks.</title>
          <description>Measurements from zero to 100 with 100 being the worst pain by Visual Analog Scale (VAS).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" spread="14.5"/>
                    <measurement group_id="O2" value="51.4" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.4" spread="18"/>
                    <measurement group_id="O2" value="44" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8" spread="23.7"/>
                    <measurement group_id="O2" value="36.7" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evoked Pain Via Algometry .</title>
        <description>Assessment of evoked pain using digital palpation examination at 18 predefined bodily sites.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Study Drug</title>
            <description>Drug&#xD;
duloxetine: Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: Placebo match duloxetine for 6 week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Evoked Pain Via Algometry .</title>
          <description>Assessment of evoked pain using digital palpation examination at 18 predefined bodily sites.</description>
          <units>Pain pressure threshold (kg/cm2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311.9" spread="115.8"/>
                    <measurement group_id="O2" value="300.8" spread="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1, 3, and 6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Duloxetine Study Drug</title>
          <description>Drug&#xD;
duloxetine: Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: Placebo match duloxetine for 6 week period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sharon Gordon, DDS</name_or_title>
      <organization>ECU SODM</organization>
      <phone>2527377125</phone>
      <email>gordons@ecu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

